Your Vision, Our Innovations, Clinical Reality!

Our Inference AI powered Drug Development Engine empowers scientists to identify better therapeutic candidates faster and at lower cost, minimizing risks in drug-like properties and toxicity to boost clinical success rates.

Top ADMET prediction and PK/PD modeling solution in Canada 2026

Boosting Drug Candidates' Clinical Success Through Smarter Discovery

Two challenges

1. High Failure Rates
Nearly 90% of drug candidates fail in clinical trials, with 45% of these failures due to poor ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties—issues often discovered too late in development [Sun et al. Acta Pharmaceutica Sinica B 2022, 12: 3049-3062].

2. Blind spot: Fragmented Intelligence
Numerous tools aim to predict ADMET outcomes, but each works differently, with its own strengths and blind spots. The result? Inconsistent predictions and no clear consensus on which truly reflect reality in animals.

Traditional tools vs PHD's Inference AI tool

Our solution: Inference-driven Integrated Intelligence

Proholistic Discovery takes a new path—combining systems thinking with inference-driven AI for ADMET prediction, Pharmacokinetics (PK), Pharmacodynamics (PD), and Systems Pharmacology modeling to guide smarter, faster drug discovery. We provide Decision-Ready Assets by resolving uncertainty—turning fragmented, noisy data into actionable intelligence that reflects actual human biology rather than just replacing existing computational tools. Our innovate technologies empower researchers to make confident, data-informed decisions early—reducing risk and improving clinical success.

Our Services

Consultation

Our consulting services integrate systems pharmacology, virtual screening, bioinformatics, and computational biology to optimize drug development strategies from early discovery through clinical trials.

With deep expertise spanning target identification, lead optimization, and clinical development, we provide science-driven, quantitative insights that enhance decision-making, reduce risk, and improve overall program success.

We collaborate with Applied Pharmaceutical Innovation (API) in Edmonton to deliver tailored, inference-driven solutions that streamline development and accelerate clinical outcomes.

As an Expert Advisor within Innovate Calgary’s Expert Advisory Program, we support member companies in advancing their drug discovery programs with mechanistic insight and data-driven strategy.

Inference AI powered Drug Development Engine

Our solution to increase clinical success by delivering early, accurate AI-driven insights that optimize therapeutic design and accelerate the delivery of effective treatments .

Inference AI powered ADMET assessment. It provides a quick and yet robust estimate of the ADMET properties of your candidates.
Customized Physiological based PKPD modeling.
- Animal PBPK/PD model tailored to your needs, validated with benchmark studies
- Include a virtual course to set up and conduct in silico studies independently

Fromuncertainty to certainty flow_vs.png

Comparison of designed and tested aptamers

Aptamer design

We offer a cutting-edge, proprietary technology for aptamer design—a faster, smarter alternative to traditional SELEX-based selection. Our AI-driven approach rapidly designs highly specific RNA/DNA aptamers for any biomolecular target, including small molecules, proteins, nucleic acids, and phospholipids, in under two weeks. This breakthrough accelerates discovery and development, saving both time and resources.

What People Say

Dr. Shairaz Baksh, President and Founder of BioImmuno Designs

"We engaged Proholistic Discovery to help us select our lead molecule. They were very efficient and professional in obtaining the structures from us, converting into formats they can use and produced an excellent summary of PK comparisons between our various structures and how it compares to a known FDA approved drug. The analysis they did for us was invaluable. It was completed quickly and was exactly what I wanted to achieve at this stage. I would highly recommend them for small molecule PK analysis and more functionalities that they have. I would certainly use them again. Excellent job PHD!

Dr. Piyush Kumar, President and CEO of WWiKY BioSciences

It is an extreme pleasure to announce that WWiKY Biosciences Inc. is working in collaboration with Proholistic Discovery, Edmonton on an Edmonton Unlimited supported 'Expert on Demand project to develop an AI-based human PK/PD model for its 'hypoxia theranostic clinical product' Hypoxycin-1 - a radiotheranostic product for imaging and treating hypoxic tumors of many cancer types.

Our commitment

Innovation

Our commitment to innovation drives us to explore new horizons in quantitative systems pharmacology. We constantly seek groundbreaking solutions to revolutionize the industry and help clients advancing their drug discovery.

Collaboration

Collaboration lies at the heart of our approach. By fostering strong partnerships with clients and industry experts, we create synergies that lead to enhanced drug development processes and ultimately, improved clinical trial success.

Quality

Quality is paramount in everything we do. From our services to our technology, we uphold the highest standards to deliver excellence and reliability in supporting drug development initiatives.

Meet Our Team

Our team at Proholistic Discovery unites 40+ years of biomedical, pharma, and AI expertise to accelerate smarter, faster drug discovery

Richard, Chih-Yuan Tseng, PhD

President

Richard is a theoretical physicist turned biotech innovator dedicated to reimagining how medicines are discovered. With over 15 years of experience across computational biology and preclinical drug development, he applies information theory, AI, and mechanistic PK/PD modeling to uncover patterns that make drug discovery faster, smarter, and more predictable. He has authored 30+ publications, holds eight patents, and has built and led computational platforms that power combination therapies and systems pharmacology strategies. As a co-founder of two biotech companies, Richard focuses on translating deep science into real-world impact. His mission is simple: a future where treatments are delivered with precision—efficiently, economically, and tailored to every patient.

Jack Tuszynski, PhD

Chief Scientific Officer

Jack is a globally recognized leader in molecular biophysics and translational drug design whose work bridges fundamental physics and life-saving therapeutics. A Professor at the University of Alberta and the Polytechnic University of Turin, and former Allard Chair in Experimental Oncology, he has spent over three decades advancing science from discovery to clinic. His research has produced more than 600 publications, 12 books, seven international patents, and over 100 competitive grants. He has mentored scientists worldwide and served on 30 journal editorial boards. Notably, his drug candidate CCI-001 has advanced into clinical trials for metastatic bladder cancer, exemplifying his commitment to transforming scientific insight into tangible patient impact. He has also founded three biotech spin-offs to accelerate real-world translation.

Winston Wang, MSc, EMBA

Chief Technology Officer

Winston is a technology and AI leader with 19 years of experience spanning drug development, global clinical research, and regulated pharmaceutical environments. He has held senior roles across both CRO and sponsor organizations, including IQVIA and Takeda, where he led complex, data-intensive clinical trial programs and advanced analytics initiatives. His work includes applying machine learning, real-world data, and AI-driven methodologies to improve clinical decision-making and development efficiency. At 35Pharma, he further integrated AI into biotech strategy and operations. He also founded Wisient Technology, architecting scalable AI-powered platforms that translate cutting-edge technology into practical solutions for life sciences and healthcare.

Advisory board

Guided by our world-renowned board of experts, we ensure scientific excellence and strategic vision at every step of our journey.

Dr. Michael Houghton (Scientific advisor)

Sir Michael Houghton, PhD and Nobel laureate in Physiology or Medicine in 2020

Pharmacology

Dr. Houghton is is the Li Ka Shing Professor of Virology at the University of Alberta where he is also the Director of the Li Ka Shing Applied Virology Institute. He is also the CSO of Applied Pharmaceutical Innovation.

Dr. James Frost, MD, PhD, and MBA

Pharmacology

Dr. Frost is President of BioMolecular Imaging, LLC. and Professor emeritus of Radiology and Neuroscience at Johns Hopkins University. He has consulted for a wide variety of pharmaceutical and biotech diagnostic and therapeutic entities.
He pioneered the first molecular imaging technologies to image neuroreceptors.

Prof. Patrick Poulin, PhD

Pharmacokinetics and Toxicology

Prof. Poulin is an Associate professor at Department of Public Health, University of Montreal and a pharmacologist and toxicologist at Consultant Patrick Poulin Inc. He is a renowned expert in DMPK predictions and First-in-Human dose projects. He also has contributed to the development of Phase I studies of several drugs with successful dose predictions.

Dr. Mohammad Ashrafuzzaman (Scientific advisor)

Prof. Mohammad Ashrafuzzaman, DsC

Membrane physics and Aptamer

Prof. Ashrafuzzaman is a Professor at Biochemistry Department of College of Science at King Saud University, Riyadh, Saudi Arabia. He specializes in applying theoretical and experimental approach to study the membrane and protein interactions of cell-targeted agents, including drugs and nanoparticles and aptamer design.